INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Back to India Desk
2026/09/27Healthcare, Pharma & Life Sciences

Ernakulam Remains Kerala's Influenza Hotspot as Doctors Warn of Festive-Season Spread and Next Year's Fever Surge

Ernakulam district continues to report the highest number of influenza cases in Kerala, with 969 confirmed cases recorded till September 26, even as doctors urge residents to curb person-to-person transmission through strict preventive habits. Health officials say the district's broader fever burden remains significant, with dengue, leptospirosis and other infections also circulating, while experts warn that El Niño could drive another spike in fever cases next April.

R

RDU Global Correspondent

Healthcare & Pharma Desk

Ernakulam, India 3h ago•5 min read
Ernakulam Remains Kerala's Influenza Hotspot as Doctors Warn of Festive-Season Spread and Next Year's Fever Surge
Editorial Photo: Ernakulam, India — Ernakulam Remains Kerala's Influenza Hotspot as Doctors Warn of Festive-Season Spread and Next Year's Fever SurgeRDU Global Media

Ernakulam continues to shoulder Kerala's heaviest influenza burden, with doctors and public health officials warning that the district's persistent fever cases demand sustained vigilance even as the current flu season begins to ease. The district had reported 969 influenza cases till September 26, the highest in the State, according to health authorities, while Kerala as a whole recorded 2,205 confirmed influenza cases during the month. The State also reported 20 deaths due to influenza, underscoring the continuing public health concern around seasonal and viral infections.

District Medical Officer Dr. R. Shahirsha said there was no marked rise in fever or influenza cases in field reports at present, but cautioned that a fresh surge could emerge next year. He linked the projected increase in fever cases in April to the El Niño phenomenon, which can alter weather patterns and create conditions favourable for disease transmission.

"There is no marked rise in fever or influenza cases as per our field reports. But there is a prediction that the El Niño phenomenon could lead to an increase in fever cases in April next year. Our target is to prevent person-to-person transmission as much as possible," Dr. Shahirsha said.

Health officials have placed particular emphasis on community-level awareness and preventive behaviour, especially in a district that remains a major travel hub and therefore more exposed to the movement of infections. The district administration has rolled out the epidemic prevention action plan, Arogyabheri, across all local bodies from September. The year-long programme is being jointly implemented by the district panchayat and the Health department and was launched in response to a rise in diseases such as H1N1, West Nile disease and chikungunya compared with last year.

According to Dr. Shahirsha, the campaign is designed to push preventive measures through public participation while reinforcing sanitation and healthy practices that can slow the spread of infectious diseases. "The focus is on implementing preventive measures through public participation and raising awareness about adopting healthy and sanitation practices to prevent the spread of infectious diseases. Health education programmes have been launched towards this end," he said.

The district's disease burden is not limited to influenza. Officials reported 58 confirmed and 12 suspected cases of leptospirosis this month, along with 649 suspected and 234 confirmed dengue cases. Four deaths due to leptospirosis have also been reported in the district, adding to concerns about the combined pressure of monsoon-linked infections and viral illnesses.

Public health observers say the timing of the current pattern is consistent with the tail end of the monsoon season, when waterborne and vector-borne diseases often remain active. Rajeev Jayadevan, convener of the Research Cell of the Indian Medical Association's Kerala State unit, said the flu season would soon subside, but noted that Ernakulam's status as a travel hub may be contributing to the continued reporting of influenza and dengue cases.

"The flu season will end soon. The district being a travel hub is one of the reasons for the continued reporting of influenza and dengue cases. As the monsoon gets over, influenza cases will subside, and so will leptospirosis cases as the ground dries up. Fever cases are persisting as the recent festive season would have led to the spread of various viruses," Jayadevan said.

The warning from doctors comes at a time when public health authorities are trying to prevent complacency after months of repeated fever alerts. While officials say there is no immediate evidence of a sharp escalation, the combination of influenza, dengue, leptospirosis and other seasonal infections has kept the district on alert. The emphasis now is on early detection, hygiene, sanitation and reducing close-contact transmission before the next seasonal cycle begins.

For residents, the message from health authorities is clear: the current lull should not be mistaken for the end of the threat. With Ernakulam still leading the State in influenza cases and with multiple infections circulating simultaneously, officials are urging households, workplaces and local bodies to maintain preventive discipline well beyond the monsoon months.

Editorial & Verification Notice

Reported by RDU Global Correspondent. Formatted and verified using real-time institutional and journalistic wire feeds. Independent reporting adhering to the RDU Global Editorial Code of Conduct.

Related Coverage

Healthcare, Pharma & Life Sciences

USFDA Scrutiny vs. Biosimilar Leadership: The Strategic Dilemma Facing Indian Pharma’s Generic Champions

Indian pharma’s biggest listed manufacturers are being pulled in opposite directions: toward higher-value biologics, complex injectables and biosimilars, and back toward the basics of manufacturing discipline under intensifying USFDA scrutiny. For Sun Pharma, Dr. Reddy’s and Cipla, the strategic prize is clear—less commoditised growth, better margins and a stronger moat against price erosion in the US generics market. But the regulatory cost of failure is rising, with Form 483 observations, warning letters and import-risk disruptions forcing expensive remediation and slowing launches. The deeper challenge is structural. India’s generic champions still depend on the US for a large share of profits while relying on China for critical APIs and intermediates. That leaves them exposed to two forms of concentration risk at once: compliance concentration in FDA-inspected plants and supply-chain concentration in upstream chemistry. The companies are now spending billions of rupees to diversify APIs, automate plants and build biologics platforms, but the transition is uneven, capital-intensive and vulnerable to any fresh USFDA setback.

Special Report (Sept 27, 2026)
Healthcare, Pharma & Life Sciences

Rio Health Raises $4.5 Million to Expand Quick Medicine Delivery Network Across Delhi NCR

Pharmacy-focused quick commerce startup Rio Health has raised $4.5 million in a pre-Series A round led by Version One Ventures, with participation from Xeed Ventures, Good Capital and Amplify. The company plans to deploy the capital to add 12 dark stores across Delhi NCR, deepen its technology stack and push annual recurring revenue beyond Rs 150 crore over the next 9 to 12 months.

4h ago
Healthcare, Pharma & Life Sciences

CBN Launches Anti-Drug Awareness Drive for Students in Jawra Under Mission Yuva Raksha

The Central Bureau of Narcotics (CBN) organized an anti-drug awareness programme for students in Jawra, Madhya Pradesh, as part of Mission Yuva Raksha and the broader Nasha Mukt Bharat campaign. The initiative aimed to educate young people about the dangers of drug abuse and strengthen community-level prevention efforts through student engagement.

1h ago